Structure-based pharmacophore models to probe anticancer activity of inhibitors of protein kinase B-beta (PKB β)

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology and Drug Discovery
• Oncology

Background:

• Protein kinase B-beta (PKBβ/Akt2) is a key regulator of cell survival and proliferation, frequently hyperactivated in solid tumors.
• Akt2's role in promoting tumor survival makes it a significant target for developing novel cancer therapeutics.
• Inhibiting Akt2 can disrupt cancer cell cycle progression and potentially lead to tumor regression.

Purpose of the Study:

• To identify novel and potent inhibitors of Akt2 using structure-based pharmacophore modeling.
• To discover new chemical scaffolds with potential anticancer activity targeting Akt2.
• To provide lead compounds for the development of future Akt2-targeted cancer therapies.

Main Methods:

• Development and validation of structure-based pharmacophore models for Akt2.
• Virtual screening of public chemical databases to identify potential Akt2 inhibitors (hits).
• Prioritization of hit compounds using drug-like filters and evaluation of their inhibitory potential.

Main Results:

• A pharmacophore model highlighting key features (3 H-bond acceptors, 1 H-bond donor, 1 hydrophobic group, 1 positive ionic charge) for Akt2 inhibition was established.
• 14 potential hit compounds with novel chemical scaffolds targeting Akt2 were identified.
• One selected hit compound demonstrated significant efficacy, inducing 68% cell apoptosis at 8 μg/ml concentration.

Conclusions:

• The study successfully identified novel chemical scaffolds, including benzamide, carboxamide, and methyl benzimidazole derivatives, as potential Akt2 inhibitors.
• These findings underscore the importance of specific pharmacophoric features for effective Akt2 inhibition.
• The identified compounds represent promising lead candidates for further preclinical development as anticancer agents targeting Akt2.